Sign inCreate account

Report workspace

Add to folder
NCT00456846TERMINATEDanonymous

An Open-Label, Phase II Study of Weekly ABI-007 as First Line Therapy for Patients With Metastatic Breast Cancer

Sponsor

Source record

Celgene

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

Nab-paclitaxel (ABI-007) targets microtubules, disrupting the mitotic spindle formation, leading to cell cycle arrest and apoptosis in cancer cells.

Indication / condition

AI-normalized

Metastatic Breast Cancer

Intervention

Source record

ABI-007

Related intelligence directories

Indication directory: Metastatic Breast CancerModality directory: small moleculeTarget directory: Nab-paclitaxel (ABI-007) targets microtubules

Source & freshness

Source record

NCT ID

NCT00456846

Original source

ClinicalTrials.gov

Source last updated

Nov 22, 2019

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00456846

Title

An Open-Label, Phase II Study of Weekly ABI-007 as First Line Therapy for Patients With Metastatic Breast Cancer

Sponsor

Celgene

Status

TERMINATED

Phase

Phase 2

Condition raw

Metastatic Breast Cancer

Condition normalized

Metastatic Breast Cancer

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Nab-paclitaxel (ABI-007) targets microtubules, disrupting the mitotic spindle formation, leading to cell cycle arrest and apoptosis in cancer cells.

Target normalized

Nab-paclitaxel (ABI-007) targets microtubules, disrupting the mitotic spindle formation, leading to cell cycle arrest and apoptosis in cancer cells.

Interventions

ABI-007

Public preview

Source record

The Phase II study of ABI-007 as a first-line therapy for metastatic breast cancer, sponsored by Celgene, aimed to evaluate its toxicity and anti-tumor activity in patients with prior taxane therapy and those without. The study's termination in May 2013 suggests potential challenges in achieving favorable efficacy or safety profiles. The competitive landscape includes established therapies like Taxol and newer agents, necessitating a thorough market analysis to assess ABI-007's positioning. The results could influence future development strategies and partnerships, particularly in the context of combination therapies or alternative indications.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

An Open-Label, Phase II Study of Weekly ABI-007 as First Line Therapy for Patients With Metastatic Breast Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 19, 2026

NCT ID

NCT00456846

Status

TERMINATED

Phase

Phase 2

Sponsor

Celgene

Executive brief

Investment-Ready Snapshot

The Phase II study of ABI-007 as a first-line therapy for metastatic breast cancer, sponsored by Celgene, aimed to evaluate its toxicity and anti-tumor activity in patients with prior taxane therapy and those without. The study's termination in May 2013 suggests potential challenges in achieving favorable efficacy or safety profiles. The competitive landscape includes established therapies like Taxol and newer agents, necessitating a thorough market analysis to assess ABI-007's positioning. The results could influence future development strategies and partnerships, particularly in the context of combination therapies or alternative indications.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 22, 2019
Internal syncJun 19, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00456846

Indication

Metastatic Breast Cancer

Modality

small molecule

Target

Nab-paclitaxel (ABI-007) targets microtubules, disrupting the mitotic spindle formation, leading to cell cycle arrest and apoptosis in cancer cells.

Intervention

ABI-007

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.